FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or antigen-binding fragment that specifically binds to CD40. Also a nucleic acid encoding the said antibody; an expression vector or pair containing the said nucleic acid; a cell containing the specified vector; a conjugate and a pharmaceutical composition containing the specified antibody are disclosed. A method for producing the said antibody is disclosed; a method for treating a cancer patient with the said antibody; a method for killing or reducing the rate of tumor growth using the said antibody; using the said antibody to produce a bispecific antibody.
EFFECT: invention makes it possible to effectively treat diseases associated with CD40.
52 cl, 22 dwg, 7 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODIES AGAINST CD40 AND APPLICATION THEREOF | 2019 |
|
RU2778572C1 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
